OakChart

YD Bio Ltd

YDESHealthcare·Biotechnology·Taiwan·Small·NASD·Nov 11 • 3:58 PM ET

6.15+0.12 (1.99%)
2026-11-12 05:47 CET
Market cap
435.68 USD m
Revenue, TTM
0.85 USD m
Net income, TTM
6.70 USD m
Free cash flow, TTM
-2.83 USD m
EPS diluted, TTM
0.09
P/E
-
Compare

Price

YDES against its 20, 50 and 200-day averages
2050200
2.505.007.5010.002.4M4.9MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26YDESclose 6.1520-day 6.0250-day 5.46200-day 5.306.1552w low

60.9% under the 52-week high of 15.72 on 8 Dec 2025. 52-week low 1.70 on 2 Jul 2026. Last 15 sessions, 80.2% high to low

Volume 0.04× normal · the line is the 50-bar volume average

Profile

YDES
52-week range, 32% of the way up
1.7015.72

YD Bio Ltd. is a biotechnology company building an integrated healthcare platform across regulated diagnostics, clinical services, and commercial healthcare markets. It operates DNA methylation-based oncology testing programs under an LDT-first strategy and provides compliant life science distribution and clinical trial supply chain services to pharmaceutical and biotechnology partners. The company's offerings include cancer detection products, regenerative ophthalmology solutions, and exosome-based technologies. YD Bio was founded on February 6, 2024 and is headquartered in Taipei, Taiwan.

Employees15
IPODec 23, 2020
Beta-0.59
ATR, 14d0.89
Rel volume0.04
Short float1.33%
Insider own80.12%
Inst own0.39%

Snapshot

6 groups

Valuation

Index-
Market Cap435.68M
Enterprise Value433.03M
Income-
Sales-
Book/sh0.06
Cash/sh0.04
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees15
IPODec 23, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B97.39
P/C163.79
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio3.46
Current Ratio5.23
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y- 6.41%
Sales past 3/5Y- -
EPS Y/Y TTM14.61%
Sales Y/Y TTM-
EPS Q/Q-116.03%
Sales Q/Q-
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own80.12%
Insider Trans0.06%
Inst Own0.39%
Inst Trans10.02%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA202.20%
SMA5012.64%
SMA20015.99%
Trades-

Technical

Shs Outstand70.84M
Shs Float14.09M
Short Float1.33%
Short Ratio0.61
Short Interest0.19M
52W High15.72 -60.88%
52W Low1.70 261.76%
Volatility15.61% 15.91%
ATR (14)0.89
RSI (14)51.25
Beta-0.59
Rel Volume0.04
Avg Volume306.73K
Volume13,294

Performance

Perf Week-11.51%
Perf Month0.82%
Perf Quarter145.02%
Perf Half Y18.27%
Perf YTD-49.55%
Perf Year-30.43%
Perf 3Y-44.14%
Perf 5Y-39.41%
Perf 10Y-
Recom-
Target Price-
Prev Close6.03
Price6.15
Change %1.99%

Peers

Mkt cap
TickerCompanyMkt cap
SLBTSL Science Holding Ltd405.09M
MENSJyong Biotech Ltd129.17M
ANIXAnixa Biosciences Inc96.65M
ALDXAldeyra Therapeutics Inc39.32M
OKYOOKYO Pharma Limited74.52M
CDIOCardio Diagnostics Holdings Inc5.68M
HINDVyome Holdings Inc11.02M
ALPSALPS Group Inc37.70M
ABVCABVC BioPharma Inc26.49M
IGCIGC Pharma Inc23.21M

Insider trading

3 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Shen Ethan PhDCEOSep 14 '26Buy3.8512,70048,89511,258,331Sep 16 04:01 PM
Shen Ethan PhDCEOSep 09 '26Buy3.933,10012,18311,245,631Sep 10 04:01 PM
Shen Ethan PhDCEOSep 04 '26Buy3.6718,37867,44711,242,531Sep 08 04:00 PM

News

latest 14 of 48
  • YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs (GlobeNewswire)
  • YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment (GlobeNewswire) -13.50%
  • YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026 (GlobeNewswire) -22.71%
  • YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute (GlobeNewswire)
  • YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute (GlobeNewswire) +8.98%
  • YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research (GlobeNewswire)
  • YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada (GlobeNewswire)
  • YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services (GlobeNewswire) -7.69%
  • YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations (GlobeNewswire) -17.75%
  • YD Bio Limited Reports Full Year 2025 Financial Results (GlobeNewswire) -5.88%
  • YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States (GlobeNewswire)
  • YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem (GlobeNewswire) -8.55%
  • YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform (GlobeNewswire)
  • YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy (GlobeNewswire) -9.89%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-0.1740.5950.408-0.576-0.022-0.125
Period202020212022202320242025
EPS, quarterly-0.2490.161-5.1214.0520.5430.104-0.985-0.65
PeriodQ3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25
Sales, annual00000.510.597
Period202020212022202320242025
Sales, quarterly00000000
PeriodQ3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25
Shares, annual14.62514.644.834.29964.7370.789
Period202020212022202320242025
Shares, quarterly4.2994.2994.2994.0344.0344.0343.4123.364
PeriodQ3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue0.850.600.510.000.000.000.00
Cost of Goods Sold Incl. D&A0.680.640.460.000.000.000.00
Gross Profit0.16-0.040.050.000.000.000.00
Selling, General and Administrative Excl. Other3.405.231.512.072.321.720.34
Research and Development1.111.600.49----
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-3.23-5.27-1.46-2.07-2.32-1.72-0.34
Interest Expense0.000.000.00----
Unusual Expense-9.853.170.001.02-6.11-10.432.19
Net Income Before Taxes6.70-8.31-1.39-2.533.798.70-2.54
Income Taxes0.00-0.000.030.020.000.000.00
Consolidated Net Income6.70-8.31-1.41-2.553.798.70-2.54
Net Income From Continuing Operations6.70-8.31-1.41-2.553.798.70-2.54
Net Income6.70-8.31-1.41-2.553.798.70-2.54
EPS (Recurring)-0.00-0.09-0.02-0.42-0.050.10-0.07
EPS (Basic, Before Extraordinaries)0.09-0.12-0.02-0.580.410.59-0.17
EPS (Diluted)0.09-0.12-0.02-0.580.410.59-0.17
EBITDA-3.13-5.06-1.36-2.07-2.32-1.72-0.34
Non-Operating Income (Expense)0.090.130.080.550.000.000.00
Other After Tax Adjustments-0.000.000.000.000.000.00
Price To Earnings Ratio----19.2817.3517.33
Price To Sales Ratio-1,362.741,398.97----
Gross Margin--7.069.92----
Operating Margin--883.31-286.45----
Net Margin--1,392.61-276.58----
Shares Outstanding70.8470.7964.734.304.8314.6414.62
Market Capitalization435.68435.6845.3847.4250.38149.47149.33

Income statement, quarterly

Currency USD, millions
Metric2026S1
Total Revenue0.85
Cost of Goods Sold Incl. D&A0.68
Gross Profit0.16
Selling, General and Administrative Excl. Other3.40
Research and Development1.11
Other Operating Expense0.00
Operating Income-3.23
Interest Expense0.00
Unusual Expense-9.85
Net Income Before Taxes6.70
Income Taxes0.00
Consolidated Net Income6.70
Net Income From Continuing Operations6.70
Net Income6.70
EPS (Recurring)-0.00
EPS (Basic, Before Extraordinaries)0.09
EPS (Diluted)0.09
EBITDA-3.13
Non-Operating Income (Expense)0.09
Gross Margin19.37
Operating Margin-382.12
Net Margin791.55
Shares Outstanding70.84
Market Capitalization435.68

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments6.013.130.000.010.010.69
Short Term Receivables0.710.260.020.020.000.00
Inventories1.880.040.000.000.000.00
Other Current Assets1.070.040.240.170.120.14
Total Current Assets9.673.470.270.200.130.83
Net Property, Plant & Equipment0.070.090.000.000.000.00
Total Investments and Advances0.000.0012.9817.73117.93116.73
Intangible Assets2.612.680.000.000.000.00
Other Assets1.430.630.000.000.000.02
Total Assets13.786.8613.2417.93118.06117.59
Short Term Debt Incl. Current Port. of LT Debt0.010.020.000.000.000.00
Accounts Payable0.410.030.000.000.000.00
Income Tax Payable-0.050.000.00--
Other Current Liabilities1.220.228.085.552.000.30
Total Current Liabilities1.640.268.085.552.000.30
Long Term Debt0.000.010.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities-0.00----
Other Liabilities14.990.002.201.187.1117.51
Total Liabilities16.640.2710.286.749.1117.81
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-2.866.592.9711.20108.9699.78
Total Shareholders Equity-2.866.592.9711.20108.9699.78
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-2.866.592.9711.20108.9699.78
Total Liabilities & Stockholders Equity13.786.8613.2417.93118.06117.59
Book Value Per Share-0.040.100.692.327.446.82
Tangible Book Value Per Share-0.080.060.692.327.446.82
Full-Time Employees154444-
Price to Book Ratio97.39-15.8220.854.111.441.43
Return on Assets-67.68-14.04-16.355.577.39-
Return on Equity--29.54-35.996.318.34-
Return on Invested Capital--21.40-85.9433.837.99-2.54
Quick Ratio4.7413.040.030.040.062.75
Current Ratio5.8813.180.030.040.062.75

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income6.70-8.31-1.41-2.553.798.70-2.54
Depreciation0.100.210.10----
Other Funds (Non Cash)-9.773.190.010.46-6.11-10.022.19
Funds from Operations-2.96-4.91-1.27-2.09-2.33-1.32-0.34
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital0.14-1.690.050.06-0.700.630.09
Income Taxes Payable--0.00-0.000.000.180.02
Cash from Operating Activities-2.82-6.60-1.22-2.02-3.02-0.69-0.25
Capital Expenditures-0.01-1.44-2.910.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.01-0.53-1.40-1.15-116.72
Purchase of Investments0.000.000.00-0.53-1.40-1.15-116.72
Sale Or Maturity of Investments0.000.000.010.000.000.000.00
Other Uses-0.510.000.000.000.000.000.00
Other Sources0.000.000.005.84101.780.000.00
Cash from Investing Activities-0.51-1.44-2.905.31100.38-1.15-116.72
Cash Dividends Paid0.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.000.00
Change in Capital Stock0.0210.707.25-5.63-101.550.00117.67
Repurchase of Common Pref Stock0.000.000.00-5.63-101.550.000.00
Sale of Common Pref Stock0.0210.707.250.000.000.00117.67
Proceedsfrom Stock Options0.009.987.250.000.000.00117.67
Issuance or Reduction of Debt, Net0.000.00-0.032.334.201.150.00
Change in Long Term Debt0.000.00-0.030.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.00-0.030.000.000.000.00
Net Financing Active Other Cash Flow0.000.17-0.100.000.000.000.00
Other Financing Activities Uses0.000.00-0.100.000.000.000.00
Cash from Financing Activities0.0210.877.11-3.29-97.341.15117.67
Exchange Rate Effect-0.030.040.06----
Net Change in Cash-3.352.883.05-0.010.01-0.690.69
Free Cash Flow-2.83-8.04-1.30-2.02-3.02-0.69-0.25
Deferred Taxes & Investment Tax Credit--0.000.030.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026S1
Cash & Short Term Investments2.66
Short Term Receivables0.56
Inventories1.89
Other Current Assets0.48
Total Current Assets5.59
Net Property, Plant & Equipment0.06
Total Investments and Advances0.00
Intangible Assets2.47
Other Assets1.94
Total Assets10.06
Short Term Debt Incl. Current Port. of LT Debt0.01
Accounts Payable0.37
Other Current Liabilities0.69
Total Current Liabilities1.07
Long Term Debt0.00
Other Liabilities4.52
Total Liabilities5.59
Non-Equity Reserves0.00
Preferred Stock - Carrying Value0.00
Common Equity4.47
Total Shareholders Equity4.47
Accumulated Minority Interest0.00
Total Equity4.47
Total Liabilities & Stockholders Equity10.06
Book Value Per Share0.06
Tangible Book Value Per Share0.03
Price to Book Ratio97.39
Return on Invested Capital149.77
Quick Ratio3.46
Current Ratio5.23

Cash flow, quarterly

Currency USD, millions
Metric2026S1
Net Income6.70
Depreciation0.10
Other Funds (Non Cash)-9.77
Funds from Operations-2.96
Extraordinary Item0.00
Changes in Working Capital0.14
Cash from Operating Activities-2.82
Capital Expenditures-0.01
Net Assets From Acquisitions0.00
Sale of Fixed Assets and Businesses0.00
Purchase or Sale of Investments0.00
Purchase of Investments0.00
Sale Or Maturity of Investments0.00
Other Uses-0.51
Other Sources0.00
Cash from Investing Activities-0.51
Cash Dividends Paid0.00
Preferred Dividends (Cash Flow)0.00
Change in Capital Stock0.02
Repurchase of Common Pref Stock0.00
Sale of Common Pref Stock0.02
Proceedsfrom Stock Options0.00
Issuance or Reduction of Debt, Net0.00
Change in Long Term Debt0.00
Issuance of Long Term Debt0.00
Reduction of Long Term Debt0.00
Net Financing Active Other Cash Flow0.00
Other Financing Activities Uses0.00
Cash from Financing Activities0.02
Exchange Rate Effect-0.03
Net Change in Cash-3.35
Free Cash Flow-2.83

Revenue breakdown

Beauty Products2025: 49.91K
Contact Lenses2025: 35.00K
Drugs2024: 143.63K 2025: 223.43K
Medical And Related Products2024: 292.86K 2025: 280.77K
Nutritional Products2024: 41.77K 2025: 5.23K
Supplements2024: 32.10K 2025: 2.47K
Taiwan2024: 510.36K 2025: 561.82K
United States2025: 35.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.33%0.2M14.1M299.82K
2026-10-151.36%0.2M14.1M284.13K
2026-09-301.26%0.2M14.1M350.76K
2026-09-150.31%0.0M14.1M245.71K
2026-08-310.09%0.0M14.1M147.07K
2026-08-140.12%0.0M14.1M133.34K
2026-07-310.12%0.0M14.1M128.04K
2026-07-150.18%0.0M14.1M128.49K
2026-06-300.08%0.0M14.1M31.04K
2026-06-150.10%0.0M14.1M18.74K
2026-05-290.12%0.0M13.9M17.64K
2026-05-150.12%0.0M13.7M18.50K
2026-04-300.16%0.0M13.6M23.64K
2026-04-150.17%0.0M13.6M25.92K
2026-03-310.18%0.0M13.7M37.11K
2026-03-130.26%0.0M13.7M37.35K
2026-02-270.28%0.0M13.7M56.55K
2026-02-130.32%0.0M13.7M68.18K
2026-01-300.38%0.1M13.7M76.29K
2026-01-150.34%0.0M13.7M79.84K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-064Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-01424B3SEC
2026-09-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-11424B3SEC
2026-08-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-11SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-05-29EFFECTEffectiveness filing by commission orderSEC
2026-05-26POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-05-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-30SEC
2026-04-3020-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-04-203/A2026-03-18SEC
2026-04-024Statement of changes in beneficial ownership of securities2026-03-31SEC
2026-04-024Statement of changes in beneficial ownership of securities2026-03-31SEC
2026-04-023Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-023Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-303Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-273Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-263Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-02-27424B3SEC
2026-02-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-26SEC
2026-02-17SCHEDULE 13G/ASEC
2026-02-05424B3SEC
2026-01-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-30SEC
2026-01-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-21SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09128.53K300
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Garrett Wealth Advisory Group, LLC0.12%
GEODE CAPITAL MANAGEMENT, LLC0.06%
Cerity Partners LLC0.05%
CITADEL ADVISORS LLC0.04%
Cypress Capital Management LLC0.04%
UBS Group AG0.04%
JANE STREET GROUP, LLC0.03%
WOLVERINE ASSET MANAGEMENT LLC0.01%
SkyView Investment Advisors, LLC0.00%
MORGAN STANLEY0.00%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.06%
Fidelity Nasdaq Composite Index ETF0.03%

OakChart. YDES. Cached 15 minutes.

Some panels did not load: ratings.